Clinical trials: Adenoma, active
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- (RIOT 4A) (NCT07192900)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- David Bartlett, MD
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Colorectal Adenomatous Polyp, Colorectal Carcinoma
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps.
- Conditions
- Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
- Trial name
- NCT05630794
- Testing
- Biopsy Procedure, Biospecimen Collection, Colonoscopy
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Pituitary Adenoma
AI in Endoscopic Transsphenoidal Surgery
This study focuses on bringing artificial intelligence into the operating room to assist with pituitary tumour surgeries performed through the nose.
- Trial name
- NCT07568366
- Testing
- Live intra-op AI analysis of endoscopic video feed, with output displayed on supplementary monitor
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
Colorectal Cancer
Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs.
Colorectal cancer (CRC) screening programs have been implemented to reduce the burden of the disease. When an advanced colonic lesions is detected, it is recommended to perform endoscopic surveillance with different intervals…
- Trial name
- NCT04967183
- Testing
- Annual FIT, Endoscopic surveillance.
- Where
- Spain
- Volunteers
- 3,788 people, healthy volunteers welcome
- Sponsor
- Fundacin Biomedica Galicia Sur
Pancreas Cancer, Lung Cancer
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
- Trial name
- NCT06196294
- Testing
- Cell therapy for solid tumors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Prolactinoma, Pituitary Tumor
The PROMISE Survey
The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas.
- Trial name
- NCT06936813
- Where
- Switzerland
- Volunteers
- 530 people
- Sponsor
- University Hospital, Basel, Switzerland
Lynch Syndrome
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers.
- Trial name
- CADLYNCH (NCT05963191)
- Testing
- Colorectal cancer screening with CAD EYE colonoscopy
- Where
- France
- Volunteers
- 272 people
- Sponsor
- PERROD Guillaume
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Pleural Mesothelioma, Mesothelioma
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior…
- Trial name
- sTEADfast (NCT07824986)
- Testing
- VT3989, gemcitabine, Vinorelbine
- Volunteers
- 350 people
- Sponsor
- Vivace Therapeutics, Inc
Cancer, Cancer, Lung
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with…
- Conditions
- Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma
- Trial name
- NIPU (NCT04300244)
- Testing
- UV1 vaccine + leukine, ipilimumab, nivolumab
- Where
- 7 sites in Australia, Denmark and 3 more
- Volunteers
- 118 people
- Sponsor
- Åslaug Helland
Neuroendocrine Tumor of Pancreas, Multiple Endocrine Neoplasia Type 1
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multiple pancreatic neuro-endocrine tumours (pNET).
- Trial name
- PRIME (NCT05037461)
- Testing
- High-dose-high precision MR-guided radiotherapy
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- J.M. de Laat
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
KLF4 Methylation, Epigenetic
KLF4 Epigenetic Modulation
The study investigates the epigenetic regulation of KLF4 during the progression from colorectal polyps to adenomas and carcinomas.
- Trial name
- POLYEP (NCT07901335)
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Mesotheliomas Pleural
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural…
- Trial name
- NCT03760575
- Testing
- Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.